Product Description
Gel-200 is an intra-articular injection utilizing cross-linked hyaluronate hydrogel and was developed to provide long-term pain relief with a single injection. a treatment for knee osteoarthritis (Sourced from: https://www.seikagaku.co.jp/en/news/news-8243911603934770397/main/0/link/43.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seikagaku
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoarthritis, Knee|Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2019-SCAR-01 | P3 |
Completed |
Injuries/wounds Unspecified |
2022-05-26 |
2022-06-09 |
Primary Endpoints|Treatments |
|
| Gel/1132 | P3 |
Completed |
Osteoarthritis, Knee |
2009-06-01 |
2019-03-21 |
Treatments |
|
| SI-6606/01 | P3 |
Completed |
Osteoarthritis, Knee |
2007-12-01 |
2019-03-21 |
Treatments |